Vemlidy FDA Approval History
FDA Approved: Yes (First approved November 10, 2016)
Brand name: Vemlidy
Generic name: tenofovir alafenamide
Dosage form: Tablets
Company: Gilead Sciences, Inc.
Treatment for: Hepatitis B
Vemlidy (tenofovir alafenamide) is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
Development Timeline for Vemlidy
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
